07666.HK
Metis Techbio-p
HKSE · Healthcare · Biotechnology · CN
HKD 13.82
+5.02%Income statement
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | 14.6M | 206.8K | 1.3M |
| Cost of Revenue | 5.0M | 4.9M | 5.8M |
| Gross Profit | 9.7M | (4.7M) | (4.5M) |
| Operating Expenses | |||
| R&D Expense | 37.6M | 38.2M | 41.1M |
| SG&A Expense | 25.8M | 9.8M | 10.1M |
| General & Admin Expense | — | — | — |
| Selling & Marketing Expense | — | — | — |
| Other Expenses | 138.74 | (24.8K) | 147.7K |
| Total Operating Expenses | 63.4M | 48.0M | 51.4M |
| Cost and Expenses | 68.3M | 52.9M | 57.2M |
| Operating Income (EBIT) | (53.7M) | (52.7M) | (55.9M) |
| Non-Operating | |||
| Interest Income | 3.1M | 3.3M | 1.7M |
| Interest Expense | 4.5M | 23.5M | 10.0M |
| Net Interest Income | (1.4M) | (20.2M) | (8.3M) |
| Other Non-Op Income/Expense | (875.6K) | (17.0M) | (26.4M) |
| Non-Operating Income (excl Interest) | (3.6M) | (6.5M) | 16.5M |
| EBT (Pre-Tax Income) | (54.6M) | (69.6M) | (82.3M) |
| Income Tax Expense | 17.1K | 1.1K | 282.92 |
| Bottom Line | |||
| Net Income | (54.6M) | (69.6M) | (82.3M) |
| Earnings from Cont. Ops | (54.6M) | (69.6M) | (82.3M) |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | (54.6M) | (69.6M) | (82.3M) |
| Per Share | |||
| Basic EPS | (HK$0.05) | (HK$0.06) | (HK$0.07) |
| Diluted EPS | (HK$0.05) | (HK$0.06) | (HK$0.07) |
| Revenue Per Share | HK$0.01 | HK$0.00 | HK$0.00 |
| Shares | |||
| Basic Shares Outstanding | 1.2B | 1.2B | 1.2B |
| Diluted Shares Outstanding | 1.2B | 1.2B | 1.2B |
| Profitability Metrics | |||
| EBITDA | (45.4M) | (41.3M) | (67.0M) |
| D&A | 4.7M | 4.8M | 5.3M |
| EBIT | (50.1M) | (46.1M) | (72.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025